Lit­tle MEI Phar­ma rock­ets up on $25M cash in­jec­tion, deep-pock­et part­ner for PhI­II AML can­cer study

Can a 4-cylin­der biotech with an un­con­ven­tion­al de­vel­op­ment part­ner help dri­ve a large­ly un­known can­cer drug through Phase III on an in­dus­try track dom­i­nat­ed by …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER